{"groups":[{"description":"Patients receive cisplatin IV on day 1 and paclitaxel IV and cetuximab IV on days 1, 8, and 15. Treatment repeats every 21 days for 3 courses. Patients then undergo evaluation of response to induction therapy. Patients with a CR at the primary tumor site proceed to group 1 of concurrent low-dose IMRT and cetuximab. Patients with a PR or SD at the primary tumor site or those with grossly positive disease at the primary tumor site proceed to group 2 of concurrent standard dose IMRT and cetuximab.","id":"FG000","title":"Overall"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Complicating disease"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Never started assigned therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"90"}],"type":"STARTED"},{"achievements":[{"comment":"This is the all treated patients for toxicity analysis","groupId":"FG000","numSubjects":"89"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"81"}],"type":"Eligible"},{"achievements":[{"comment":"This is the eligible and treated patients for secondary efficacy endpoints","groupId":"FG000","numSubjects":"80"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"56"}],"type":"CR to Induction Therapy"},{"achievements":[{"comment":"This is the primary study population for the primary endpoint (24-month PFS).","groupId":"FG000","numSubjects":"44"}],"type":"CR and Treated With 5400 cGy IMRT"},{"achievements":[{"groupId":"FG000","numSubjects":"78"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on March 17, 2010, accrued its first patient on August 11, 2010, and closed to accrual on October 19, 2011, with an accrual of 90 patients from 16 ECOG-affiliated institutions."}